1993 Fiscal Year Final Research Report Summary
Multicytokine-producintg mononuclear cell therapy for cancer patients
| Project/Area Number |
04670788
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Saga Medical School |
|---|
Principal Investigator |
KATANO Mitsuo SAGA MEDICAL SCHOOL, FACULTY OF MEDICINE, ASSISTANT PROFESSOR, 医学部, 講師 (10145203)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ABE Masamitsu SAGA MEDICAL SCHOOL, FACULTY OF MEDICINE, ASSISTANT PROFESSOR, 医学部, 講師 (20136427)
KUBOTA Eiro SAGA MEDICAL SCHOOL, FACULTY OF MEDICINE, ASSISTANT PROFESSOR, 医学部, 講師 (50170030)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Keywords | Malignant tumors / OK-432 / Cytokine / Adoptive immunothrapy / Intratumor injection / Mononuclear cells / TGIF / Frozen spleen cells |
|---|
| Research Abstract |
Based on the experimental findings, multicytokine-producing cytotxic mononuclear cells(MCCM) therapy was performed for 1)patients with gastric cancer, 2)those with recurrent or inoperable brain tumors, and 3)those with advanced head and neck cancers. In this report, clinical effects and safety of the MCCM therapy were studied and summarized. Results : 1) OK-432-activated peripheral blood mononuclear cells(MCCM : 10^7 cells) were locally administered to the tumor site for the treatment of 22 patients with gastric cancer before operation, and the resulted specimens were examined macroscopically and hitopathologically. Disappearance, extensive necrosis and focal necrosis of the tumors were found in 1, 3 and 4 cases, respectively. No particular side effects were encountered. In addition, a case with postoperative recurrent hepatic metastasis received intra-arterial injection of cryopreserbed splenn-derived ononuclear cells(MCCM). In this case, speed of the tumor grouth was slightly suppres
… More
sed. 2)MCCM therapy was done in 18 cases with head and neck cancers and histopapthological examination was completed in 9 out of the 18 cases. Complete response, partial response and mild response were detected in 3, 5 and 1 cases, respectively. A patient with neck cancer showing cystic formation received intratumor injection of MCCM alone. She showed a significant reduction of the tumor and a rapid decrease of CEA levels in the cystic fluid. In addition, two patients who received intratumor injection of cryopreserved allogeneic spleen-derived MCCM had a remarkable reduction of tumors. Curative operation was fortunately performed in one of the 2 patients. A transient fever immediately after the MCCM therapy was often ecncountered.
3)Five patients with recurrent and/or inoperable glioblastoma received the MCCM therapy. Patients receiveing the MCCM therapy showed a siginificant long mean survival times compared with patients not receiveing the MCCM therapy (MCCM vs control : 26 months vs 12 months). However, severe side effects including high fever and hypotension were encoutered. Less
|
